{"filing":{"accession_number":"0001213900-26-103733","cik":"0001985062","ticker":"PBMWW","company_name":"PSYENCE BIOMEDICAL LTD.","form":"6-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"ea0306807-6k_psyence.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390026103733/ea0306807-6k_psyence.htm"},"events":[{"id":35277,"run_id":32489,"accession_number":"0001213900-26-103733","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The press release announces a binding term sheet between Psyence BioMed's wholly-owned subsidiary (TIRC) and PsyLabs granting exclusive U.S. development, supply, and distribution rights to pharmaceutical-grade ibogaine. This constitutes a material acquisition of exclusive rights and a strategic licensing arrangement with significant financial terms (up to $1.3M in milestone payments, annual exclusivity fees, and royalties on net sales). The transaction is binding and expected to be superseded by a definitive agreement by November 30, 2026, making it a material M\u0026A-type activity that would affect a reasonable investor's assessment of the company's strategic position and future revenue potential.","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-28","form":"6-K","submitted_at":null,"items":[{"id":39277,"accession_number":"0001213900-26-103733","item_number":"EX-99.1","item_title":"ea030680701ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The press release announces a binding term sheet between Psyence BioMed's wholly-owned subsidiary (TIRC) and PsyLabs granting exclusive U.S. development, supply, and distribution rights to pharmaceutical-grade ibogaine. This constitutes a material acquisition of exclusive rights and a strategic licensing arrangement with significant financial terms (up to $1.3M in milestone payments, annual exclusivity fees, and royalties on net sales). The transaction is binding and expected to be superseded by a definitive agreement by November 30, 2026, making it a material M\u0026A-type activity that would affect a reasonable investor's assessment of the company's strategic position and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:09:47.754483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39277,"accession_number":"0001213900-26-103733","item_number":"EX-99.1","item_title":"ea030680701ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The press release announces a binding term sheet between Psyence BioMed's wholly-owned subsidiary (TIRC) and PsyLabs granting exclusive U.S. development, supply, and distribution rights to pharmaceutical-grade ibogaine. This constitutes a material acquisition of exclusive rights and a strategic licensing arrangement with significant financial terms (up to $1.3M in milestone payments, annual exclusivity fees, and royalties on net sales). The transaction is binding and expected to be superseded by a definitive agreement by November 30, 2026, making it a material M\u0026A-type activity that would affect a reasonable investor's assessment of the company's strategic position and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:09:47.754483+00:00","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-28"}]}